ArticleLa Radiologia medica2026
Radiation therapy and overall survival in male breast cancer: a multicenter analysis of 302 patients.
Article in La Radiologia medica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis multicenter study aimed to assess the efficacy and the prognostic role of adjuvant radiation therapy and other factors in a cohort of male breast cancer patients (MaBC) treated in 10 Italian centers within the Clinical Oncology Breast Cancer Group.
methodsThis retrospective study included patients diagnosed with MaBC between 2005 and 2023. Demographic, clinical, tumor, and treatment data were retrieved from medical records. Information on treatment-related acute and late adverse events was also collected. Disease-free survival (DFS) was calculated from surgery to recurrence or last follow-up visit, overall survival (OS) from diagnosis to death or last follow-up visit.
resultsOverall, 302 patients were included (median age 69). Most were diagnosed with stage I-IIIa (75%; vs 25% stage IIIb-IV), invasive ductal carcinoma (88%) and luminal-like tumors (88%). Nearly all patients underwent mastectomy (96%), 31% received adjuvant chemotherapy, 83% endocrine therapy (mainly tamoxifen), and 33% radiation therapy. At a median follow-up of 79 months, DFS and OS were significantly associated, among others, with stage (p < 0.05). In stage IIIb-IV patients, omission of radiation therapy was associated with higher recurrence risk (hazard ratio, HR = 18.8, p < 0.001) and worse OS (HR = 6.45, p < 0.001). Acute radiation therapy-related adverse events occurred in 28% of patients, mostly graded 1-2, but no severe late toxicity was observed.
conclusionsThis large retrospective cohort study showed that MaBC patients treated with multi-modality therapies achieved favorable outcomes. Specifically, radiation therapy significantly improved survival in advanced stages with low incidence of late adverse events further supporting its role in daily clinical practice.
Indexed as
Identifiers
42804144What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.